Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Abstract Following publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442–1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All c...

Full description

Bibliographic Details
Main Authors: Simona Sacco, Lars Bendtsen, Messoud Ashina, Uwe Reuter, Gisela Terwindt, Dimos-Dimitrios Mitsikostas, Paolo Martelletti
Format: Article
Language:English
Published: BMC 2019-05-01
Series:The Journal of Headache and Pain
Online Access:http://link.springer.com/article/10.1186/s10194-019-0972-5

Internet

http://link.springer.com/article/10.1186/s10194-019-0972-5

Similar Items